Literature DB >> 16647662

Fibromyalgia and myofascial pain syndromes and the workers' compensation environment: an update.

Radford J Hayden1, Dean S Louis, Christopher Doro.   

Abstract

Fibromyalgia and myofascial pain syndromes are terms used to describe a constellation of complaints ranging from generalized aches to specific tender trigger points often accompanied by fatigue, depression, and sleep disturbances. In the past 5 years, research has been directed primarily at determining the pathophysiology of fibromyalgia and myofascial pain syndromes and the treatment of patients' comorbidities to alleviate their symptomatology. Controversy exists as to whether fibromyalgia and myofascial pain syndromes represent a specific pathology or are merely terms to describe clinical conditions that provide patients with the reassurance that their symptoms are real and help clinicians with therapeutic direction. In the occupational health setting, this uncertainty can lead to significant difficulty in determining short- and long-term disability and assigning culpability to an individual's work environment.

Entities:  

Mesh:

Year:  2006        PMID: 16647662     DOI: 10.1016/j.coem.2005.11.001

Source DB:  PubMed          Journal:  Clin Occup Environ Med        ISSN: 1526-0046


  3 in total

1.  Prediction of similarities among rheumatic diseases.

Authors:  Pinar Yildirim; Cinar Ceken; Reza Hassanpour; Mehmet Resit Tolun
Journal:  J Med Syst       Date:  2010-11-03       Impact factor: 4.460

2.  Efficacy of EMLA cream phonophoresis comparison with ultrasound therapy on myofascial pain syndrome of the trapezius: a single-blind, randomized clinical study.

Authors:  Nilgun Ustun; Fatma Arslan; Ayhan Mansuroglu; Deniz Inanoglu; Abdullah Erman Yagız; Hayal Guler; Ayse Dicle Turhanoglu
Journal:  Rheumatol Int       Date:  2013-10-23       Impact factor: 2.631

3.  Effectiveness of Ultrasound Therapy on Myofascial Pain Syndrome of the Upper Trapezius: Randomized, Single-Blind, Placebo-Controlled Study.

Authors:  Mustafa Aziz Yildirim; Kadriye Öneş; Gökşen Gökşenoğlu
Journal:  Arch Rheumatol       Date:  2018-03-23       Impact factor: 1.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.